Rep. Josh Gottheimer Sells Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on March 17th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/24/2025.
• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 3/24/2025.
• Sold $1,001 – $15,000 in shares of Flywire (NASDAQ:FLYW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Disco (OTCMKTS:DSCSY) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Shopify (NYSE:SHOP) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 3/19/2025.
• Sold $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 3/19/2025.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock remained flat at $131.87 during mid-day trading on Friday. The stock has a 50 day moving average of $130.29 and a 200-day moving average of $104.16. The company has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the company from $119.00 to $132.00 in a report on Friday, January 31st. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $106.23.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Intra-Cellular Therapies by 124.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 133 shares in the last quarter. Accredited Wealth Management LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $28,000. GAMMA Investing LLC increased its stake in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies in the third quarter worth $97,000. 92.33% of the stock is owned by institutional investors and hedge funds.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.